District of Columbia GLP-1 Lawsuit Overview
If you live in District of Columbia and were diagnosed with NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) after taking a GLP-1 drug such as Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, or Rybelsus, you may be eligible to file a claim in the federal GLP-1 NAION MDL (MDL 3163).
All GLP-1 NAION claims — regardless of where the plaintiff lives — are consolidated in MDL 3163 in the Eastern District of Pennsylvania under Judge Karen Marston. You do not need to travel to Pennsylvania to file. Your local attorney can handle your case as part of the MDL.
3 Years
Discovery Rule May Apply
District of Columbia Statute of Limitations Details
The District of Columbia generally applies a 3-year period for personal injury claims, with accrual/discovery arguments depending on the injury and notice facts.
Who Qualifies in District of Columbia?
To file a GLP-1 NAION claim as a District of Columbia resident, you generally need:
- A documented prescription for Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, or Trulicity
- An ophthalmologist's diagnosis of NAION or sudden optic nerve-related vision loss
- NAION developed during or after your GLP-1 drug use (not before)
- Filing within District of Columbia's 3-year statute of limitations window
How the MDL Works for District of Columbia Residents
Even though MDL 3163 is located in Pennsylvania, District of Columbia residents can participate without traveling. Here's how:
- You hire a District of Columbia-licensed attorney or a national mass tort firm
- Your case is filed in the MDL in Pennsylvania (or transferred there)
- All major MDL proceedings are handled by the Plaintiffs' Steering Committee
- You participate through your attorney, primarily via written correspondence and phone
- If your case goes to individual trial, it may be remanded to a federal court in District of Columbia
District of Columbia State Bar Resources
To find a licensed attorney in District of Columbia, you can use the official state bar's attorney referral service:
Visit District of Columbia State Bar →
Neighboring State Resources
Key Cities in District of Columbia
GLP-1 drug users across District of Columbia — including Washington — are eligible to participate in MDL 3163 regardless of their city.